medigraphic.com
ISSN 0016-3813 (Print)

2003, Number 2

<< Back Next >>

Gac Med Mex 2003; 139 (2)

Hematopoietic Progenitor Cell Transplantation

I. Introduction.
II. Treatment for Cytomegalic Virus-Related Infection.
III. Non-Myeloablative Allogenic Transplantation (NMAT): the Experiences of Puebla and Monterrey, Mexico.
IV. Up-Date in

Vela-Ojeda J, Gómez-Morales E, Ruiz-Argüelles GJ, López-Hernández M

Language: Spanish
References: 70
Page: 148-160
PDF size: 120.30 Kb.


Text Extraction

No abstract


REFERENCES

  1. Lungman P, Plotkin SA. Workshop of CMV disease: Definitions, clinical severity scores and new syndromes. Scand J Infect Dis 1995;suppl99:87-89.

  2. Mathe G, Amiel JL, Schwarzemberg L, Cattan A, Schneider M. Adoptive immunotherapy of acute leukemias: experimental and clinical results. Cancer Res 1965;25:1525-1531.

  3. Yu C, Storb R, Mathey B, et al. DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment. Blood 1995;86:4376-4381.

  4. Liso A, Stockerl-Goldstein KE, Aufferman-Gretzinger S, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2000;6:621-627.

  5. Small EJ, Fratesi P, Deese DM et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18:3894-3903.

  6. Preiksaitis JK. The cytomegalovirus “Safe” Blood products: Is leukoreductionEquivalent to Antibody Screening. Transf Med Rev 2000; 14(2):112-136

  7. Zaia JA. Prevention of cytomegalovirus Disease in Hematopoietic Stem Cell Transplantation. Clin Inf Dis 2002;35: 999-1004.

  8. Zaia JA. Prevention and management of CMV-related problems after hematopoietic stem cell transplantation. Bone Marr Transplant 2002;29:633-638.

  9. Burns LJ, Miller W, Kandaswamy C et al. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Bone Marr Transplan 2002;30:945-951.

  10. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, González-Llano O, Cantú OE, Hernández NE. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transpl 2000;25:131-133.

  11. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B. Editorial: Porqué se están haciendo los minitrasplantes de médula ósea?. Rev Invest Clín Méx 2001;53:110-111.

  12. Giralt S, Estey E, Albitar M, van Besien K et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeoablative therapy. Blood 1997;89:4531-4536.

  13. Slavin S, Nagler A, Naparstek E, Kapelushnik Y et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematological diseases. Blood 1998;91:756-763.

  14. Carella AM, Lerma E, Dejana A, Corsetti MT, Celesti L, Bruni R, Benvenuto F, Figari O, Parodi C, Carlier P, Florio G, Lercari G, Valbonesi M, Casarino L, De Stefano F, Geniram A, Venturino M, Tedeschi L, Palmieri G, Piaggio G, Podesta M, Frassoni F, Van Lint MT, Marmont AM, Bacigalupo A. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias. Haematologica 1998;83:904-909.

  15. Ruiz-Argüelles GJ. “The Mexican approach” to conduct non-myeloablative stem cell transplantation. Eur J Haematol 2001;67:335.

  16. Ruiz-Argüelles GJ. Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: Results of the Mexican approach. Int J Hematol 2002;76(Suppl 1):376-379.

  17. Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Argüelles A, González-Llano O, Cantú OG, Jaime-Pérez JC. Results of an outpatient-based stem cell allotransplant program using non-myeloablative conditioning regimens. Am J Hematol 2001;66:241-244.

  18. Thomas ED. Hematopoietic stem cell transplantation. Sci Am 1995; 272:38-47.

  19. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B, Cantú-Rodríguez OG, Jaime-Pérez JC, González-Llano O. Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica 2002;87:894-896.

  20. Ruiz-Argüelles GJ. Foro Clínico: El efecto de injerto contra tumor en leucemia granulocítica crónica. Rev Invest Clín Mex 2002;54:154-160.

  21. Gómez Almaguer D. The simplification of the stem cell transplantation procedures in developing countries has resulted in cost lowering and availability to more patients. Int J Hematol 2002;76(Suppl 1):380-382.

  22. Giralt S. Complications of non-myeloablative stem cell transplantation. En Giralt S, Slavin S (editores): Non-myeloablative stem cell transplantation. Darwin Scientific Publishing. Abingdom, UK. 2000. pp.139-148.

  23. Ruiz-Argüelles GJ. Simplification, not demystification nor trivializacion of stem cell transplantation. Haematologica 2001;86:E07.

  24. Giralt S. Update on non-myeloablative stem cell transplantation for hematologic malignancies. Int J Hematol 2002;76(Suppl 1):368-375.

  25. Ruiz-Argüelles GJ, López-Martínez B, Gómez-Rangel D, Estrada E, Marín-López A, Bravo-Hernández G, Hernández JM. Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: A single institution experience. Hematology 2003, en prensa.

  26. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B, Ponce-de-León S, Cantú-Rodríguez OG, Jaime-Pérez JC. No cytomegalovirus-related deaths after non-ablative stem cell allografts. Hematology 2002;7:95-99.

  27. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Gómez-Almaguer D, López-Martínez B, Abreu-Díaz G, Bravo G, Jaime-Pérez JC. Features of the engraftment of allogeneic hematopoietic stem cells using reduced-intesity conditioning regimens. Leukemia Lymph 2001;42:145-150.

  28. Ruiz-Argüelles GJ, López-Martínez B, Santellán-Olea MR, Abreu-Díaz G, Reyes-Núñez V, Ruiz-Argüelles A, Garcés-Eisele J. Follow up of hemopoietic chimerism in individuals given allogeneic hemopoietic stem cell allografts using an immunosuppressive, non-myeloablative conditioning regimen: A prospective study in a single institution. Leukemia Lymph 2002;43:1509-1511.

  29. Ruiz-Argüelles GJ, Gómez-Almaguer D. El efecto de injerto contra tumor en el tratamiento del cáncer: Rompiendo dogmas. Hemos (Venezuela) 2002. En prensa.

  30. Ruiz-Argüelles GJ. Un acento original en el concierto de las ideas.... Rev Invest Clin Méx 2000:221-222.

  31. 22 Gómez-Almaguer D, David Gómez-Almaguer D, Ruiz-Argüelles GJ, Tarín-Arzaga LC, González-Llano O, Jaime-Pérez JC, López-Martínez B, Cantú-Rodríguez OG, Herrera-Garza JL. Reduced-intensity stem cell transplantation in children and adolescents: The Mexican experience. Biol Blood Marrow Transpl 2003, en prensa.

  32. Alarcón-Segovia D, Ruiz-Argüelles A, Llorente L. Broken dogma: Penetration of autoantibodies into living cells. Immunol Today 1996;17:163-164.

  33. Quesenberry PJ, Stewart FM, Becker P, Emmons R, Hsieh C, Werme K, Habibian H, Reilly J, McAuliffe C, Dooner M, Carlson J, Miller C, Lambert JF, Colvin GA, Pang L, Benoit BO, Zhong S, Wang H, Damon J. Stem cell transplantation without myeloablation in immunocompetent recipients. En Giralt S, Slavin S (editores): Non myeloablative stem cell transplantation. Darwin Scientific Publishing. Abingdon, Oxfordshire, UK. 2000. pp 11-16.

  34. Odom LF, August CS, Githens JH, Humbert JR, Morse H, Peakman D, Sharma B, Rusnak SL, Johnson FB. Remission of relapsed leukaemia during a graft-versus-host reaction. A “graft-versus-leukaemia reaction” in man? Lancet 1978;2(8089):537-40.

  35. Weiden PL, Sullivan KM, Fluornoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft versus host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981;304:1529-1533.

  36. Hematology: Landmark papers of the twentieth century. Lichtman MA, Spivak JL, Boxer LA, Shattil SJ, Henderson ES (editores). Academic Press. San Diego, U.S.A. 2000, pp. 741-747.

  37. Giralt S, Estey E, Albitar M, van Besien K et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeoablative therapy. Blood 1997;89:4531-4536.

  38. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O´Brien S et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16:2817-2824.

  39. Carella AM, Lerma E, Dejana A, Corsetti MT, Celesti L, Bruni R, Benvenuto F, Figari O, Parodi C, Carlier P, Florio G, Lercari G, Valbonesi M, Casarino L, De Stefano F, Geniram A, Venturino M, Tedeschi L, Palmieri G, Piaggio G, Podestá M, Frassoni F, Van Lint MT, Marmont AM, Bacigalupo A. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias. Haematologica 1998;83:904-909.

  40. Champlin R. Nonmyeloablative chemotherapy with allogeneic hematopoietic transplantation as adoptive immunotherapy for malignancies. En Schechter GP, Hoffman R, Schrier SL.: Hematology 1999. The American Society of Hematology Education Program Book. Washington, U.S.A. 1999. pp.413-416.

  41. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, González-Llano O, Cantú OE, Hernández NE. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transpl 2000;25:131-133.

  42. Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Argüelles A, González-Llano O, Cantú OG, Jaime-Pérez JC. Results of an outpatient-based stem cell allotransplant program using non-myeloablative conditioning regimens. Am J Hematol 2001;66:241-244.

  43. Ruiz-Argüelles GJ. El efecto de injerto contra tumor en leucemia granulocítica crónica. Rev Invest Clín Mex 2002;54:154-160.

  44. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B, Cantú-Rodríguez OG, Jaime-Pérez JC, González-Llano O. Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica 2002;87:894-896.

  45. Feinstein L, Sandmaier B, Maloney D, McSweeney PA, Maris M, Flowers C, Radich J, Little MT, Nash RA, Cauncey T, Wolfrey A, Georges G, Kiem HP, Zaucha JM, Blume KG, Shizuru J, Niederweiser D, Storb R. Non-myeloablative hematopoietic stem cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. Ann N Y Acad Sci 2001;938:328-337.

  46. Storb R, Champlin R, Riddell SR, Murata M, Bryant S, Warren EH. Non-myeloablative transplants for malignant disease. En Schechter GP, Broudy VC, Williams ME.: Hematology 2001. The American Society of Hematology Education Program Book. Washington, U.S.A. 2002. pp. 375-391.

  47. Childs R, Barrett. Graft-versus-tumor effects following non-myeoablative stem cell transplantation. En Giralt S, Slavin S (editores): Non myeloablative stem cell transplantation. Darwin Scientific Publishing. Abingdon, Oxfordshire, UK. 2000. pp 113-126.

  48. Childs R, Clave E, Tisdale J, Plante M, Hensel N, Barret AJ. Succesful treatment of metastatic renal cell carcinoma with a non-myeloablative allogeneic peripheral blood progenitor cell transplant: Evidence for a graft-versus.tumor effect. J Clin Oncol 1999;17:2044-2051.

  49. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B. Editorial: ¿Porqué se están haciendo los minitrasplantes de médula ósea?. Rev Invest Clín Méx 2001;53:110-111.

  50. Ruiz-Argüelles GJ. Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: Results of the Mexican approach. Int J Hematol 2002;76 (Suppl 1):376-379.

  51. Goldman JM, Horowitz MM. The International Bone Marrow Transplant Registry. Int J Hematol 2002 Aug;76 Suppl 1:393-7.

  52. Fujimaki K, Maruta A, Yoshida M, Kodama F, Matsuzaki M, Fujisawa S, Kanamori H, Ishigatsubo Y. Immune reconstitution assessed during five years after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001 Jun;27(12):1275-81.

  53. Akpek G. Clinical grading in chronic graft-versus-host disease: is it time for change?. Leuk Lymphoma 2002 Jun;43(6):1211-20.

  54. Ancin I, Ferra C, Gallardo D, Peris J, Berlanga J, Gonzalez JR. Do corticosteroids add any benefit to standard GVHD prophilaxis in allogeneic BMT? Bone Marrow Transplant 2001; 28:39-45.

  55. Akpek G, Lee SM, Anders V, Vogelsang GB. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001;7(9):495-502.

  56. Arora M, Wagner JE, Davies SM, Blazar BR, Defor T, Enright H, Miller WJ, Weisdorf DF. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001;7(5):265-73.

  57. Ogawa H, Soma T, Hosen N, Tatekawa T, Tsuboi A, Oji Y, Tamaki H, Kawakami M, Ikegame K, Murakami M, Fujioka T, Kim EH, Oka Y, Sugiyama H. Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation. Transplantation 2002 Jul 27;74(2):236-43.

  58. Fassas AB, Morris C, Badros A, Van Rhee F, Tricot G. Separating graft-versus-tumor from graft-versus-host reactions. Leuk Lymphoma 2002 Apr;43(4):725-33.

  59. Clark FJ, Chakraverty R. Role of dendritic cells in graft-versus-host disease. J Hematother Stem Cell Res 2002 Aug;11(4):601-16.

  60. French LE, Alcindor T, Shapiro M, McGinnis KS, Margolis DJ, Porter D, Leonard DG, Rook AH, Foss F. Identification of amplified clonal T cell populations in the blood of patients with chronic graft-versus-host disease: positive correlation with response to photopheresis. Bone Marrow Transplant 2002 Oct;30(8):509-15.

  61. Foss FM, Gorgun G, Miller KB. Extracorporeal photopheresis in chronic graft-versus-host disease. Bone Marrow Transplant 2002 May;29(9):719-25.

  62. Halle P, Paillard C, D’Incan M, Bordigoni P, Piguet C, De Lumley L, Stephan JL, Berger M, Rapatel C, Demeocq F, Kanold J. Successful extracorporeal photochemotherapy for chronic graft-versus-host disease in pediatric patients. J Hematother Stem Cell Res 2002 Jun;11(3):501-12.

  63. Sunil A. Overview of the use of photopheresis I chronic GVHD. Blood and Marrow Transplantation Reviews 2002,12(4).

  64. Engelhard D, Cordonnier C, Shaw PJ, Parkalli T, Guenther C, Martino R, Dekker AW, Prentice HG, Gustavsson A, Nurnberger W, Ljungman P. The Infectious Disease Working Party of the European Bone Marrow Transplantation (IDWP-EBMT). Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol 2002 May;117(2):444-50.

  65. American Thoracic Society. Targeted tuberculin testing and treament of latent tuberculosis infection. Am J Crit Care Med 2000;161:S221-47.

  66. Boeckh M. Prevention of viral infections in hematopoietic stem cell transplant recipients. Hematology, the American Society of Hematology Education Program Book 2001:400-05.

  67. Sullivan KM. Vaccine-preventable infections: Guidelines for active and passive immunizations for hematopoietic stem cell transplantation. Hematology, the American Society of Hematology Education Program Book 2001:413-415.

  68. Trask PC, Paterson A, Riba M, Brines B, Griffith K, Parker P, Weick J, Steele P, Kyro K, Ferrara J. Assessment of psychological distress in prospective bone marrow transplant patients. Bone Marrow Transplant 2002 Jun;29(11):917-25.

  69. Siston AK, List MA, Daugherty CK, Banik DM, Menke C, Cornetta K, Larson RA. Psychosocial adjustment of patients and caregivers prior to allogeneic bone marrow transplantation. Bone Marrow Transplant 2001 Jun;27(11):1181-8.

  70. Kupst MJ, Penati B, Debban B, Camitta B, Pietryga D, Margolis D, Murray K, Casper J. Cognitive and psychosocial functioning of pediatric hematopoietic stem cell transplant patients: a prospective longitudinal study. Bone Marrow Transplant 2002 Nov;30(9):609-17.




2020     |     www.medigraphic.com